Predictors of respiratory decline in myotonic dystrophy type 1 (DM1): a longitudinal cohort study

被引:0
|
作者
Marco Mazzoli
Alessandra Ariatti
Giancarlo Garuti
Virginia Agnoletto
Riccardo Fantini
Alessandro Marchioni
Giuliana Galassi
机构
[1] University Hospitals of Modena,Neurology Unit, Department of Biomedical, Metabolic and Neural Sciences
[2] AUSL Modena,Pneumology Unit, Santa Maria Bianca Hospital
[3] University Hospitals of Modena,Cardiology Unit
[4] University Hospitals of Modena,Respiratory Disease Unit, Department of Medical and Surgical Sciences
来源
Acta Neurologica Belgica | 2021年 / 121卷
关键词
Myotonic dystrophy; CTG trinucleotide repeat; Forced vital capacity; Non invasive ventilation; Cardiac comorbidities;
D O I
暂无
中图分类号
学科分类号
摘要
We studied 33 patients affected by juvenile and adult myotonic dystrophy type 1 (DM1). The aim of the study was to assess clinical and laboratory parameters that could predict the requirement of noninvasive ventilation (NIV) in DM1. Secondary outcome was to assess the interplay between genetic profile, muscle impairment severity and presence of cardiac comorbidities.Patients with genetic diagnosis of DM1 were recruited. An abnormal trinucleotide repeat (CTG) expansion of dystrophy protein kinase gene (DMPK) on chromosome 19q13.3 was the prerequisite for inclusion. The number of triplet repeats was measured in genomic DNA to classify subjects. A multidisciplinary team evaluated the patients every 6–8 months up to 18 years with serial cardiological and respiratory function assessments. Neurological progression was monitored using a validated DM1-specific rating scale (MIRS). Independent variables considered for the study outcomes were gender, genetic status, age of presentation, MIRS scores, and results of pulmonary function tests (PFTs).Patients were 17 males (51.5%) and 16 females (48.5%). 16 cases were younger than mean age of 31.4 years, the remaining 17 were up to 65. 12 subjects (36.4%) underwent NIV during follow up. Cardiac comorbidities were detected in 63.6% of cases and in 91% of patients in NIV. Among PFTs, forced vital capacity (FVC) was a reliable indicator of respiratory decline. FVC values were significantly associated with clinical muscle severity assessed by MIRS.Severity of muscular impairment, CTG expansion size, age and presence of cardiac comorbidities predict respiratory impairment in DM1
引用
收藏
页码:133 / 142
页数:9
相关论文
共 50 条
  • [31] 'Mitotic drive' of expanded CTG repeats in myotonic dystrophy type 1 (DM1)
    Khajavi, M
    Tari, AM
    Patel, NB
    Tsuji, K
    Siwak, DR
    Meistrich, ML
    Terry, NHA
    Ashizawa, T
    HUMAN MOLECULAR GENETICS, 2001, 10 (08) : 855 - 863
  • [32] Hyperinsulinemia of myotonic dystrophy type 1 (DM1) might be inhibited using voglibose
    Kinoshita, M
    Imai, T
    Satoh, M
    Itoh, T
    Isoda, K
    Hasegawa, H
    Mitarai, M
    Tochigi, S
    Yonemoto, K
    Hirose, K
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 238 : S515 - S515
  • [33] Swallowing evaluation in Mexican presymptomatic patients with Myotonic Dystrophy Type 1 (DM1)
    Marquez-Quiroz, L.
    Franco-Guerrero, A. A.
    Curiel-Leal, M. D.
    Murillo-Melo, N. M.
    Leyva-Garcia, N.
    Escobar-Cedillo, E.
    Valadez-Jimenez, V. M.
    Cisneros-Vega, B.
    Magana-Aguirre, J. J.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2018, 26 : 439 - 440
  • [34] Mitotic drive of expanded CTG repeats in myotonic dystrophy type 1 (DM1).
    Khajavi, M
    Tari, AM
    Patel, NB
    Tsuji, K
    Meistrich, ML
    Terry, NHA
    Ashizawa, T
    AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 67 (04) : 348 - 348
  • [35] New nomenclature and DNA testing guidelines for myotonic dystrophy type 1(DM1)
    Gonzalez, I
    Ohsawa, N
    Singer, RH
    Devillers, M
    Ashizawa, T
    Balasubramanyam, A
    Cooper, TA
    Khajavi, M
    Lia-Baldini, AS
    Miller, G
    Philips, AV
    Timchenko, LT
    Waring, J
    Yamagata, H
    Barbet, JP
    Klesert, TR
    Tapscott, SJ
    Roses, AD
    Wagner, M
    Baiget, M
    Martorell, L
    Browne, GB
    Eymard, B
    Gourdon, G
    Junien, C
    Seznec, H
    Carey, N
    Gosling, M
    Maire, P
    Gennarelli, M
    Sato, S
    Ansved, T
    Kvist, U
    Eriksson, M
    Furling, D
    Chen, EJ
    Housman, DE
    Luciano, B
    Siciliano, M
    Spring, N
    Shimizu, M
    Eddy, E
    Morris, GE
    Krahe, R
    Furuya, H
    Adelman, J
    Pribnow, D
    Furutama, D
    Mathieu, J
    Hilton-Jones, D
    NEUROLOGY, 2000, 54 (06) : 1218 - 1221
  • [36] Hyperinsulinemia of myotonic dystrophy Type 1 (DM1) might be inhibited using Voglibose
    Kinoshita, Masanobu
    Imai, Tomihiko
    Satoh, Masao
    Isoda, Kazuo
    Hasegawa, Hajime
    Mitarai, Tetsuya
    Takahama, Misato
    Ohnuki, Manabu
    Hirose, Kazuhiko
    NEUROMUSCULAR DISORDERS, 2006, 16 : S123 - S123
  • [37] Haplotype Analysis of the Myotonic Dystrophy Type 1 (DM1) Locus in the Korean Population
    Kwon, Min-Jung
    Lee, Seung-Tae
    Kim, Byoung Joon
    Sung, Duk Hyun
    Kim, Jong-Won
    Ki, Chang-Seok
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2010, 40 (02): : 156 - 162
  • [38] Video Hand Opening Time (vHOT) in Myotonic Dystrophy Type 1 (DM1)
    Puwanant, Araya
    Statland, Jeffrey
    Dilek, Nuran
    Moxley, Richard
    Thornton, Charles
    NEUROLOGY, 2012, 78
  • [39] Multidisciplinary care of patients with Myotonic Dystrophy type 1 (DM1) in South Aquitaine
    Flabeau, Olivier
    Bisson, Thomas
    M S-MEDECINE SCIENCES, 2021, 37 : 32 - 35
  • [40] Videofluoroscopic Swallowing Findings and a Follow-Up Study in Myotonic Dystrophy Type 1 (DM1)
    Umemoto, George
    Furuya, H.
    Kitashima, A.
    Kikuta, T.
    DYSPHAGIA, 2010, 25 (04) : 384 - 384